Our mission: to redefine the standard of care in hair loss

Minoxidil doesn’t work the same way for everyone, and part of the reason may be happening inside the hair follicle. A 2026 review reports that approximately 60% of users may not achieve visible improvement, highlighting an important question in hair-loss research: why do some follicles respond while others don’t?

#Minoxidil#AndrogeneticAlopecia#AGA#HairScience#Pharmacology#DermatologyReference: Dias FR, Yong SS, FitzGerald H, Sinclair RD, Bhoyrul B. *Front Pharmacol.* 2026;16:1718208.

Menopause changes more than reproductive hormones. It can also change the environment in which hair follicles grow.

Hair loss around menopause is an important area of women’s health, yet dedicated clinical evidence remains limited.

This World Menopause Day, let’s include hair in the conversation.

Reference: Gupta AK, Economopoulos V, Mann A, Wang T, Mirmirani P. *Menopause and hair loss in women: exploring the hormonal transition.* Maturitas. 2025;198:108378.

#WorldMenopauseDay#FemalePatternHairLoss#WomensHealth#Menopause#HairScience#Dermatology

AGA is common, but its prevalence is easy to underestimate. Up to 50% of men and up to 40% of women are affected. By age 50, half of all men show signs of AGA; by age 70, prevalence reaches up to 80% in men and up to 50% in women, with a marked increase after menopause.

A condition this common deserves continued scientific attention.

Sources: Landells I, et al. A Canadian Consensus on Androgenetic Alopecia: Approach and Management. J Cutan Med Surg. 2025;29(5 Suppl):5S-14S. doi:10.1177/12034754251368849; Bhoyrul B, et al. Expanding the therapeutic landscape of minoxidil for androgenetic alopecia. Front Pharmacol. 2026;16:1718208. doi:10.3389/fphar.2025.1718208

#AndrogeneticAlopecia#AGA#HairLoss#HairScience#Dermatology

Hair loss is visible but its psychological impact isn’t. Research is increasingly showing that the experience of androgenetic alopecia can extend beyond the scalp. This World Mental Health Day, we’re recognizing the full picture.

Reference: Kong Y, Shang Y, Zhang L. Front Psychiatry. 2025;16:1705957.

#WorldMentalHealthDay#AndrogeneticAlopecia#AGA#HairLoss#MentalHealth#Dermatology

Our new website is live. Explore Triple Hair’s mission, our research approach, and the science behind our ongoing work in androgenic alopecia.

Discover our commitment to advancing clinical research, combination therapy approaches, and innovation in hair loss science.

Visit us at triplehair.ca

#TripleHair#Biopharma#ClinicalResearch#AGA#HairLossResearch#Dermatology#Innovation

Hair loss is often described as if the follicle simply “stops growing.”

The biology is more nuanced. In androgenetic alopecia, the changes happen gradually, across repeated hair-growth cycles. Understanding what is happening at the follicular level helps explain why AGA is a progressive condition and why the biology behind hair loss matters when studying potential treatments.

This serves as the basis for grasping the follicle and pursuing further research into answers. 

#AndrogeneticAlopecia#AGA#HairScience#HairBiology#HairLossResearch#Dermatology#TrichologyReference: Chen S, Li L, Ding W, Zhu Y, Zhou N. *Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment.* Drug Des Devel Ther. 2025;19:7349–7363. doi:10.2147/DDDT.S542000.

Androgenetic alopecia affects both men and women.

Research suggests that up to 50% of women may experience androgenetic alopecia by age 70. Female pattern hair loss can differ in its presentation and characteristics, making it an important area of ongoing research.

Understanding who is affected, how hair loss presents, and the biology behind it helps build a clearer picture of androgenetic alopecia.

#TripleHair#AndrogeneticAlopecia#HairScience#HairLossResearch#WomensHealth#Dermatology#ClinicalResearch

We’re heading to Vienna for EADV Congress 2026, September 30–October 3.

We’re looking forward to connecting with dermatologists, researchers, and industry colleagues and exchanging perspectives on the evolving science of androgenic alopecia.

If you’ll be attending, let’s connect. See you in Vienna. 

#EADV2026#EADV#Dermatology#AndrogenicAlopecia#AGA#HairLossResearch#ClinicalResearch#TripleHair

The most common form of hair loss, and still one of the most undertreated.

Androgenetic alopecia affects up to 80% of men and up to 50% of women by age 70 (Bhoyrul et al., 2026), with real consequences for confidence, identity, and quality of life.

One of the most common conditions in medicine remains one of the most under-researched. That gap deserves serious science.

#AndrogeneticAlopecia#HairLoss#DiseaseAwareness#QualityOfLife#Dermatology

A recent review highlights that approximately 60% of patients using topical minoxidil may see no visible improvement. For a condition affecting millions of people, treatment response remains an important area of ongoing research. This is not about dismissing established therapies. It is about understanding where the evidence stands today, where limitations remain, and where scientific questions still need answers.

In research, an unmet need is often where the most important questions begin.

Reference: Bhoyrul B, et al. Expanding the therapeutic landscape of minoxidil for androgenetic alopecia.
Front Pharmacol. 2026;16:1718208.

#AndrogenicAlopecia#ClinicalResearch#HairLoss#AGA#Dermatology#PatientOutcomes